advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Company profile
Ticker
IDXG, IDGGW
Exchange
Website
CEO
Jack Stover
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Interpace Diagnostics Group, Inc., PDI INC, PROFESSIONAL DETAILING INC
SEC CIK
Corporate docs
IRS number
222919486
IDXG stock data
Latest filings (excl ownership)
8-K
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2023 Financial and Business Results
12 Mar 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Departure of Directors or Certain Officers
16 Nov 23
8-K
Interpace Biosciences Announces Record Third Quarter 2023 Financial and Business Results
8 Nov 23
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Entry into a Material Definitive Agreement
27 Oct 23
DEFA14A
Additional proxy soliciting materials
22 Sep 23
DEF 14A
Definitive proxy
22 Sep 23
8-K
Interpace Biosciences Announces Record Second Quarter 2023 Financial and Business Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Transcripts
IDXG
Earnings call transcript
2020 Q3
21 Jan 21
IDXG
Earnings call transcript
2020 Q2
21 Oct 20
IDXG
Earnings call transcript
2020 Q1
25 Jun 20
IDXG
Earnings call transcript
2019 Q3
13 Nov 19
IDXG
Earnings call transcript
2019 Q2
13 Aug 19
IDXG
Earnings call transcript
2019 Q1
14 May 19
IDXG
Earnings call transcript
2018 Q4
19 Mar 19
IDXG
Earnings call transcript
2018 Q3
13 Nov 18
IDXG
Earnings call transcript
2018 Q2
9 Aug 18
IDXG
Earnings call transcript
2018 Q1
15 May 18
Latest ownership filings
SC 13G/A
Singer Douglas Mark
12 Feb 24
4
Christopher McCarthy
6 Feb 24
4
Christopher McCarthy
1 Aug 23
3
Christopher McCarthy
3 May 23
SC 13G/A
Singer Douglas Mark
10 Feb 23
SC 13G
Singer Douglas Mark
10 Feb 22
4
VIJAY AGGARWAL
2 Feb 22
3
VIJAY AGGARWAL
2 Feb 22
SC 13D/A
Kamin Peter
1 Feb 22
SC 13D/A
Kamin Peter
13 Jan 22
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.03 mm | 5.03 mm | 5.03 mm | 5.03 mm | 5.03 mm | 5.03 mm |
Cash burn (monthly) | 15.67 k | 106.42 k | 174.67 k | 34.92 k | (no burn) | (no burn) |
Cash used (since last report) | 93.41 k | 634.49 k | 1.04 mm | 208.18 k | n/a | n/a |
Cash remaining | 4.94 mm | 4.40 mm | 3.99 mm | 4.82 mm | n/a | n/a |
Runway (months of cash) | 315.2 | 41.3 | 22.8 | 138.2 | n/a | n/a |
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Feb 24 | Christopher McCarthy | Common Stock | Grant | Acquire A | No | No | 0 | 10,000 | 0.00 | 45,644 |
31 Jul 23 | Christopher McCarthy | Common Stock | Grant | Acquire A | No | No | 0 | 25,000 | 0.00 | 35,644 |